U
IPXL

UBS’s Impax Laboratories, Inc. IPXL Stock Holding History

UBS’s Portfolio IPXL Stock Details IPXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$9K Buy
400
+300
+300% +$7.68K ﹤0.01% 8984
2014
Q2 		$3K Hold
100
– – ﹤0.01% 9911
2014
Q1 		$3K Hold
100
– – ﹤0.01% 9908
2013
Q4 		$3K Buy
+100
New +$2.23K ﹤0.01% 9923

Other funds holding IPXL

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

UBS's IPXL Position: Q3 2014 in Review

UBS reduced its Impax Laboratories, Inc. (IPXL) stake by 29% in Q3 2014, selling an estimated $55K and leaving 5,158 shares worth $122K. The position accounts for ﹤0.01% of the portfolio, ranked #5760.

UBS first reported a position in IPXL in Q2 2013 and has held it in 6 quarters since. The position peaked at $516K in Q1 2014. 162 funds tracked by Wall St. Rank hold IPXL as of Q3 2014.

  • UBS held 5,158 shares of Impax Laboratories, Inc. worth $122K as of Q3 2014.
  • UBS sold 2,149 Impax Laboratories, Inc. shares in Q3 2014, an estimated $55K.
  • Impax Laboratories, Inc. made up ﹤0.01% of UBS's portfolio in Q3 2014, its #5760 holding.
  • UBS first reported a position in Impax Laboratories, Inc. in Q2 2013 and has held it in 6 quarters since.
  • UBS's Impax Laboratories, Inc. position peaked at $516K in Q1 2014.
  • 162 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.